Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

were Grade 1/2 in nature and clinically manageable. Two global pivotal studies are ongoing in = 2nd line (WU-KONG1 Part B) and 1st line setting (WU-KONG28), respectively, in NSCLC patients with EGFR ...

A review of modern treatment strategies for skin cancer includes recommendations for addressing irAEs with immunotherapy for nonmelanoma skin cancers.

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

"Understanding the additional pathways that promote progression from a precancerous ... In addition, the combined inhibition ...

This is proving to be a time-consuming process, as discussions of this nature are complex ... with a clear regulatory pathway to accelerate approval for ST-920 using eGFR slope at 52 weeks across ...